281221-45-2

Basic information

• Product Name: 4-((S)-2-tert-Butoxycarbonylamino-3-cyclohexyl-proprionylamino)-3-hydroxy-azepane-1-carboxylic acid benzyl ester
• Synonyms: 4-((S)-2-tert-Butoxycarbonylamino-3-cyclohexyl-proprionylamino)-3-hydroxy-azepane-1-carboxylic acid benzyl ester
• CAS NO: 281221-45-2
• Molecular Weight: 517.666
• Mol File: 281221-45-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-((S)-2-tert-Butoxycarbonylamino-3-cyclohexyl-proprionylamino)-3-hydroxy-azepane-1-carboxylic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-((S)-2-tert-Butoxycarbonylamino-3-cyclohexyl-proprionylamino)-3-hydroxy-azepane-1-carboxylic acid benzyl ester(281221-45-2)
• EPA Substance Registry System: 4-((S)-2-tert-Butoxycarbonylamino-3-cyclohexyl-proprionylamino)-3-hydroxy-azepane-1-carboxylic acid benzyl ester(281221-45-2)

Safety Data

• Hazardous Substances Data: 281221-45-2(Hazardous Substances Data)

Upstream product

• 150989-61-0 4(R,S)-amino-3(R,S)-hydroxyazepane-1-carboxylic acid benzyl ester 

Relevant articles and documents

Protease inhibitors

The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.